Friday, 15 Dec 2017


Reactive Arthritis

Prof Robert Inman gave a great summary of the state of the art in reactive arthritis (ReA).

Increasing Incidence of Paradoxical Autoimmune Disease with Biologics?

With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.


Romosozumab vs Alendronate in Postmenopausal Osteoporosis

Poster 318 presented at the ACR on Sunday morning caught attention of many, highlighting updates in phase 3 active controlled study of romosozumab vs alendronate in patients with postmenopausal osteoporosis with high risk of fracture.

Key Takeaways from ACR Review Course

The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.

2018 Changes for MOC: More Options, But Is It Better?

Responding to criticisms that the 10 year maintenance of certification exam is expensive, time-consuming, and not reflective of clinical practice, the American Board of Internal Medicine recently issued changes to their requirements, allowing more options for physicians to recertify.

BMS Featured Presentations from ACR 2017

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

Abbvie's Robust ACR Presentations

AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in San Diego.

Lilly's New Data at ACR 2017

Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif.

Crescendo ACR Presentations

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov.

ACR 2017 Playbook

The annual ACR/ARHP meeting, which begins today, Sunday November 5th, is for many the premier meeting in rheumatology. The good news is that RheumNow and its expanded faculty will cover the meeting today and each day until Thursday. I haven’t missed an ACR meeting since 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 15,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, Costco gone wild and a sold-out Margaritaville concert. Here's my ACR Playbook.

Ironwood Featured Presentations

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017. The meeting is hosted by the American College of Rheumatology and Association of Rheumatology Health Professionals.